{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T09:33:47Z","timestamp":1773740027528,"version":"3.50.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T00:00:00Z","timestamp":1712966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T00:00:00Z","timestamp":1712966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC 112-2314-B-002 131-MY3"],"award-info":[{"award-number":["NSTC 112-2314-B-002 131-MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005762","name":"National Taiwan University Hospital","doi-asserted-by":"publisher","award":["112-IF0004"],"award-info":[{"award-number":["112-IF0004"]}],"id":[{"id":"10.13039\/501100005762","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s00535-024-02101-2","type":"journal-article","created":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T06:01:45Z","timestamp":1712988105000},"page":"609-620","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Dynamic change of metabolic dysfunction-associated steatotic liver disease in patients with hepatitis C virus infection after achieving sustained virologic response with direct-acting antivirals"],"prefix":"10.1007","volume":"59","author":[{"given":"Chen-Hua","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Ping","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Jen","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pin-Nan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Yu","family":"Kao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Lin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng-Shun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Lueng","family":"Shih","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Yuan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Chang","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shang-Chin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tung-Hung","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tai-Chung","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Jen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei-Jer","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2442-7952","authenticated-orcid":false,"given":"Jia-Horng","family":"Kao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,13]]},"reference":[{"key":"2101_CR1","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(23)01320-X","volume":"402","author":"M Martinello","year":"2023","unstructured":"Martinello M, Solomon SS, Terrault NA, et al. Hepatitis C. Lancet. 2023;402:1085\u201396.","journal-title":"Lancet"},{"key":"2101_CR2","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jhep.2020.11.040","volume":"74","author":"F Negro","year":"2021","unstructured":"Negro F. Residual risk of liver disease after hepatitis C virus eradication. J Hepatol. 2021;74:952\u201363.","journal-title":"J Hepatol"},{"key":"2101_CR3","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77:1335\u201347.","journal-title":"Hepatology"},{"key":"2101_CR4","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJMra2033539","volume":"384","author":"P Cacoub","year":"2021","unstructured":"Cacoub P, Saadoun D. Extrahepatic manifestations of chronic HCV infection. N Engl J Med. 2021;384:1038\u201352.","journal-title":"N Engl J Med"},{"key":"2101_CR5","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","volume":"397","author":"EE Powell","year":"2021","unstructured":"Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021;397:2212\u201324.","journal-title":"Lancet"},{"key":"2101_CR6","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1470-2045(22)00078-X","volume":"23","author":"DJH Tan","year":"2022","unstructured":"Tan DJH, Ng CH, Lin SY, et al. Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis. Lancet Oncol. 2022;23:521\u201330.","journal-title":"Lancet Oncol"},{"key":"2101_CR7","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1136\/gutjnl-2020-320622","volume":"69","author":"G Targher","year":"2020","unstructured":"Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut. 2020;69:1691\u2013705.","journal-title":"Gut"},{"key":"2101_CR8","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/gutjnl-2020-323082","volume":"71","author":"A Mantovani","year":"2022","unstructured":"Mantovani A, Petracca G, Beatrice G, et al. Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. Gut. 2022;71:156\u201362.","journal-title":"Gut"},{"key":"2101_CR9","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1007\/s10620-015-3760-3","volume":"60","author":"HK Dyal","year":"2015","unstructured":"Dyal HK, Aguilar M, Bhuket T, et al. Concurrent obesity, diabetes, and steatosis increase risk of advanced fibrosis among HCV patients: a systematic review. Dig Dis Sci. 2015;60:2813\u201324.","journal-title":"Dig Dis Sci"},{"key":"2101_CR10","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1007\/s10620-015-3983-3","volume":"61","author":"HK Dyal","year":"2016","unstructured":"Dyal HK, Aguilar M, Bartos G, et al. Diabetes mellitus increases risk of hepatocellular carcinoma in chronic hepatitis C virus patients: a systematic review. Dig Dis Sci. 2016;61:636\u201345.","journal-title":"Dig Dis Sci"},{"key":"2101_CR11","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1111\/jvh.13167","volume":"26","author":"N Peleg","year":"2019","unstructured":"Peleg N, Issachar A, Sneh Arbib O, et al. Liver steatosis is a major predictor of poor outcomes in chronic hepatitis C patients with sustained virological response. J Viral Hepat. 2019;26:1257\u201365.","journal-title":"J Viral Hepat"},{"key":"2101_CR12","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jhep.2016.10.017","volume":"66","author":"AJ van der Meer","year":"2017","unstructured":"van der Meer AJ, Feld JJ, Hofer H, et al. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. J Hepatol. 2017;66:485\u201393.","journal-title":"J Hepatol"},{"key":"2101_CR13","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1007\/s10620-020-06457-2","volume":"66","author":"JN Benhammou","year":"2021","unstructured":"Benhammou JN, Moon AM, Pisegna JR, et al. Nonalcoholic fatty liver disease risk factors affect liver-related outcomes after direct-acting antiviral treatment for hepatitis C. Dig Dis Sci. 2021;66:2394\u2013406.","journal-title":"Dig Dis Sci"},{"key":"2101_CR14","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.cgh.2018.10.038","volume":"17","author":"E Degasperi","year":"2019","unstructured":"Degasperi E, D\u2019Ambrosio R, Iavarone M, et al. Factors associated with increased risk of de novo or recurrent hepatocellular carcinoma in patients with cirrhosis treated with direct-acting antivirals for HCV infection. Clin Gastroenterol Hepatol. 2019;17:1183-91.e7.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2101_CR15","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/hep.26644","volume":"59","author":"M Wiese","year":"2014","unstructured":"Wiese M, Fischer J, L\u00f6bermann M, et al. Evaluation of liver disease progression in the German hepatitis C virus (1b)-contaminated anti-D cohort at 35 years after infection. Hepatology. 2014;59:49\u201357.","journal-title":"Hepatology"},{"key":"2101_CR16","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"76","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;76:1542\u201356.","journal-title":"J Hepatol"},{"key":"2101_CR17","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1111\/apt.16346","volume":"53","author":"Y Fouad","year":"2021","unstructured":"Fouad Y, Lazarus JV, Negro F, et al. MAFLD considerations as a part of the global hepatitis C elimination effort: an international perspective. Aliment Pharmacol Ther. 2021;53:1080\u20139.","journal-title":"Aliment Pharmacol Ther"},{"key":"2101_CR18","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1136\/gut.2002.009936","volume":"53","author":"L Cast\u00e9ra","year":"2004","unstructured":"Cast\u00e9ra L, H\u00e9zode C, Roudot-Thoraval F, et al. Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis. Gut. 2004;53:420\u20134.","journal-title":"Gut"},{"key":"2101_CR19","doi-asserted-by":"crossref","first-page":"7845","DOI":"10.1038\/s41598-018-26293-9","volume":"8","author":"K Shimizu","year":"2018","unstructured":"Shimizu K, Soroida Y, Sato M, et al. Eradication of hepatitis C virus is associated with the attenuation of steatosis as evaluated using a controlled attenuation parameter. Sci Rep. 2018;8:7845.","journal-title":"Sci Rep"},{"key":"2101_CR20","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1111\/apt.14554","volume":"47","author":"T Tada","year":"2018","unstructured":"Tada T, Kumada T, Toyoda H, et al. Viral eradication reduces both liver stiffness and steatosis in patients with chronic hepatitis C virus infection who received direct-acting anti-viral therapy. Aliment Pharmacol Ther. 2018;47:1012\u201322.","journal-title":"Aliment Pharmacol Ther"},{"key":"2101_CR21","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1097\/MEG.0000000000001106","volume":"30","author":"N Kobayashi","year":"2018","unstructured":"Kobayashi N, Iijima H, Tada T, et al. Changes in liver stiffness and steatosis among patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response. Eur J Gastroenterol Hepatol. 2018;30:546\u201351.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2101_CR22","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12876-023-02732-4","volume":"23","author":"B Niu","year":"2023","unstructured":"Niu B, Zang W, Zhou H, et al. Regression in hepatic fibrosis in elderly Chinese patients with hepatitis C receiving direct-acting antiviral treatment. BMC Gastroenterol. 2023;23:102.","journal-title":"BMC Gastroenterol"},{"key":"2101_CR23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0269641","volume":"17","author":"N Chuaypen","year":"2022","unstructured":"Chuaypen N, Siripongsakun S, Hiranrat P, et al. Improvement of liver fibrosis, but not steatosis, after HCV eradication as assessment by MR-based imaging: role of metabolic derangement and host genetic variants. PLoS ONE. 2022;17: e0269641.","journal-title":"PLoS ONE"},{"key":"2101_CR24","volume":"13","author":"N Kawagishi","year":"2018","unstructured":"Kawagishi N, Suda G, Nakamura A, et al. Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis. PLoS ONE. 2018;13: e0209615.","journal-title":"PLoS ONE"},{"key":"2101_CR25","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/hepr.13899","volume":"53","author":"Y Tokuchi","year":"2023","unstructured":"Tokuchi Y, Suda G, Kawagishi N, et al. Hepatitis C virus eradication by direct-acting antivirals causes a simultaneous increase in the prevalence of fatty liver and hyper low-density lipoprotein cholesterolemia without an increase in body weight. Hepatol Res. 2023;53:595\u2013606.","journal-title":"Hepatol Res"},{"key":"2101_CR26","doi-asserted-by":"crossref","first-page":"702","DOI":"10.3390\/diagnostics12030702","volume":"12","author":"A Trifan","year":"2022","unstructured":"Trifan A, Stratina E, Rotaru A, et al. Changes in liver steatosis using controlled attenuation parameter among patients with chronic hepatitis C infection treated with direct-acting antivirals therapy who achieved sustained virological response. Diagnostics (Basel). 2022;12:702.","journal-title":"Diagnostics (Basel)"},{"key":"2101_CR27","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jceh.2018.06.009","volume":"9","author":"G Rout","year":"2019","unstructured":"Rout G, Nayak B, Patel AH, et al. Therapy with oral directly acting agents in hepatitis C infection is associated with reduction in fibrosis and increase in hepatic steatosis on transient elastography. J Clin Exp Hepatol. 2019;9:207\u201314.","journal-title":"J Clin Exp Hepatol"},{"key":"2101_CR28","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.3390\/jcm9092702","volume":"9","author":"C Graf","year":"2020","unstructured":"Graf C, Welzel T, Bogdanou D, et al. Hepatitis C clearance by direct-acting antivirals impacts glucose and lipid homeostasis. J Clin Med. 2020;9:2702.","journal-title":"J Clin Med"},{"key":"2101_CR29","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.jhep.2016.12.022","volume":"66","author":"T Karlas","year":"2017","unstructured":"Karlas T, Petroff D, Sasso M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017;66:1022\u201330.","journal-title":"J Hepatol"},{"key":"2101_CR30","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/hep.23425","volume":"51","author":"L Cast\u00e9ra","year":"2010","unstructured":"Cast\u00e9ra L, Foucher J, Bernard PH, et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology. 2010;51:828\u201335.","journal-title":"Hepatology"},{"key":"2101_CR31","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.jhep.2017.05.005","volume":"67","author":"VW Wong","year":"2017","unstructured":"Wong VW, Petta S, Hiriart JB, et al. Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter. J Hepatol. 2017;67:577\u201384.","journal-title":"J Hepatol"},{"key":"2101_CR32","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1128\/JCM.03548-14","volume":"53","author":"CH Liu","year":"2015","unstructured":"Liu CH, Liang CC, Liu CJ, et al. Comparison of Abbott RealTime HCV genotype II with versant line probe assay 2.0 for hepatitis C virus genotyping. J Clin Microbiol. 2015;53:1754\u20137.","journal-title":"J Clin Microbiol"},{"key":"2101_CR33","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","volume":"43","author":"RK Sterling","year":"2006","unstructured":"Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology. 2006;43:1317\u201325.","journal-title":"Hepatology"},{"key":"2101_CR34","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jhep.2008.02.008","volume":"48","author":"L Castera","year":"2008","unstructured":"Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol. 2008;48:835\u201347.","journal-title":"J Hepatol"},{"key":"2101_CR35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-137-1-200207020-00006","volume":"137","author":"D Prati","year":"2002","unstructured":"Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002;137:1\u201310.","journal-title":"Ann Intern Med"},{"key":"2101_CR36","doi-asserted-by":"crossref","first-page":"563","DOI":"10.3390\/jcm9020563","volume":"9","author":"DG Ribaldone","year":"2020","unstructured":"Ribaldone DG, Sacco M, Saracco GM. The effect of viral clearance achieved by direct-acting antiviral agents on hepatitis C virus positive patients with type 2 diabetes mellitus: a word of caution after the initial enthusiasm. J Clin Med. 2020;9:563.","journal-title":"J Clin Med"},{"key":"2101_CR37","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/liv.14676","volume":"41","author":"A Ciancio","year":"2021","unstructured":"Ciancio A, Ribaldone DG, Dotta A, et al. Long-term follow-up of diabetic and non-diabetic patients with chronic hepatitis C successfully treated with direct-acting antiviral agents. Liver Int. 2021;41:276\u201387.","journal-title":"Liver Int"},{"key":"2101_CR38","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/cid\/ciz304","volume":"70","author":"AA Butt","year":"2020","unstructured":"Butt AA, Yan P, Aslam S, et al. Hepatitis C virus (HCV) treatment with directly acting agents reduces the risk of incident diabetes: results from electronically retrieved cohort of HCV infected veterans (ERCHIVES). Clin Infect Dis. 2020;70:1153\u201360.","journal-title":"Clin Infect Dis"},{"key":"2101_CR39","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3390\/biomedicines11020271","volume":"11","author":"W Elgretli","year":"2023","unstructured":"Elgretli W, Chen T, Kronfli N, et al. Hepatitis C virus-lipid interplay: pathogenesis and clinical impact. Biomedicines. 2023;11:271.","journal-title":"Biomedicines"},{"key":"2101_CR40","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/hep.23219","volume":"50","author":"KE Corey","year":"2009","unstructured":"Corey KE, Kane E, Munroe C, et al. Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up. Hepatology. 2009;50:1030\u20137.","journal-title":"Hepatology"},{"key":"2101_CR41","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/hep.27424","volume":"61","author":"EG Meissner","year":"2015","unstructured":"Meissner EG, Lee YJ, Osinusi A, et al. Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients. Hepatology. 2015;61:790\u2013801.","journal-title":"Hepatology"},{"key":"2101_CR42","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1080\/00365521.2018.1473486","volume":"53","author":"JR Carvalho","year":"2018","unstructured":"Carvalho JR, Velosa J, Serejo F. Lipids, glucose and iron metabolic alterations in chronic hepatitis C after viral eradication - comparison of the new direct-acting antiviral agents with the old regimens. Scand J Gastroenterol. 2018;53:857\u201363.","journal-title":"Scand J Gastroenterol"},{"key":"2101_CR43","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.jhep.2008.06.022","volume":"49","author":"S McPherson","year":"2008","unstructured":"McPherson S, Jonsson JR, Barrie HD, et al. Investigation of the role of SREBP-1c in the pathogenesis of HCV-related steatosis. J Hepatol. 2008;49:1046\u201354.","journal-title":"J Hepatol"},{"key":"2101_CR44","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s43162-023-00197-1","volume":"35","author":"A El-Ghandour","year":"2023","unstructured":"El-Ghandour A, Youssif T, Ibrahim W, et al. The effect of different direct antivirals on hepatic steatosis in nondiabetic and na\u00efve hepatitis C-infected Egyptian patients. Egypt J Intern Med. 2023;35:12.","journal-title":"Egypt J Intern Med"},{"key":"2101_CR45","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.3390\/medicina57111226","volume":"57","author":"F Mihai","year":"2021","unstructured":"Mihai F, Trifan A, Stanciu C, et al. L3 skeletal muscle index dynamics in patients with HCV-related compensated cirrhosis following sustained virological response after direct acting antiviral treatment. Medicina (Kaunas). 2021;57:1226.","journal-title":"Medicina (Kaunas)"},{"key":"2101_CR46","doi-asserted-by":"crossref","first-page":"745","DOI":"10.2169\/internalmedicine.6029-20","volume":"60","author":"R Sakamori","year":"2021","unstructured":"Sakamori R, Yamada R, Shinkai K, et al. Improvement of skeletal muscle mass after ledipasvir and sofosbuvir treatment for hepatitis C virus in decompensated liver cirrhosis. Intern Med. 2021;60:745\u201350.","journal-title":"Intern Med"},{"key":"2101_CR47","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/jvh.13763","volume":"30","author":"N Chadha","year":"2023","unstructured":"Chadha N, Turner A, Sterling RK. Prevalence and predictors of abnormal alanine aminotransferase in patients with HCV who have achieved SVR. J Viral Hepat. 2023;30:73\u20138.","journal-title":"J Viral Hepat"},{"key":"2101_CR48","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1111\/jvh.12883","volume":"25","author":"A Olveira","year":"2018","unstructured":"Olveira A, Dom\u00ednguez L, Troya J, et al. Persistently altered liver test results in hepatitis C patients after sustained virological response with direct-acting antivirals. J Viral Hepat. 2018;25:818\u201324.","journal-title":"J Viral Hepat"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-024-02101-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-024-02101-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-024-02101-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T05:35:48Z","timestamp":1731735348000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-024-02101-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,13]]},"references-count":48,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["2101"],"URL":"https:\/\/doi.org\/10.1007\/s00535-024-02101-2","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,13]]},"assertion":[{"value":"5 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}